COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,761 Articles (22,502 medRxiv, 8,259 bioRxiv)

Most recent first Previous |  Page 1738: Articles 17371-17380  | Next

Adequate knowledge of COVID-19 impacts good practices amongst health profession students in the Philippines
Dalanon, J., Redoble, R., Belotindos, J.-A., Delos Reyes, C., Fabillar, J., Armero, M. S., Locsin, R., Suzuki, Y., Okura, K., Matsuka, Y.
10.1101/2021.02.18.431919 — Posted: 2021-02-19
Probing the SAM Binding Site of SARS-CoV-2 nsp14 in vitro Using SAM Competitive Inhibitors Guides Developing Selective bi-substrate Inhibitors
Devkota, K., Schapira, M., Perveen, S., Khalili Yazdi, A., Li, F., Chau, I., Ghiabi, P., Hajian, T., Loppnau, P., Bolotokova, A., Satchell, K. J., Wang, K., Li, D., Liu, J., Smil, D., Luo, M., Jin, J., Fish, P. V., Brown, P. J., Vedadi, M.
10.1101/2021.02.19.424337 — Posted: 2021-02-19
Delivery of recombinant SARS-CoV-2 envelope protein into human cells
Hutchison, J. M., Capone, R., Luu, D. D., Hadziselimovic, A., Van Horn, W. D., Sanders, C. R.
10.1101/2021.02.18.431684 — Posted: 2021-02-19
Efficiency Improvements and Discovery of New Substrates for a SARS-CoV-2 Main Protease FRET Assay
Drazic, T., Kuehl, N., Leuthold, M. M., Behnam, M. A., Klein, C. D.
10.1101/2021.02.19.431973 — Posted: 2021-02-19
Viral genetic sequencing identifies staff transmission of COVID-19 is important in a community hospital outbreak
Masoli, J., Jeffries, A., Temperton, B., Auckland, C., Michelsen, M., Warwick-Dugdale, J., Manley, R., Farbos, A., Ellard, S., Knight, B., Bewshea, C., Sambles, C., Harrison, J. W., Bunce, B., Carr, A., Hattersley, A. T., Michell, S. L., Studholme, D.
10.1101/2021.02.18.21250737 — Posted: 2021-02-19
SARS-CoV-2 variant evolution in the United States: High accumulation of viral mutations over time likely through serial Founder Events and mutational bursts.
Tasakis, R. N., Samaras, G., Jamison, A., Lee, M., Paulus, A., Whitehouse, G., Verkoczy, L., Papavasiliou, F. N., Diaz, M.
10.1101/2021.02.19.431311 — Posted: 2021-02-19 Discussion: Onsite
Antiviral activity of influenza A virus defective interfering particles against SARS-CoV-2 replication in vitro through stimulation of innate immunity
Rand, U., Kupke, S. Y., Shkarlet, H., Hein, M. D., Hirsch, T., Marichal-Gallardo, P., Cicin-Sain, L., Reichl, U., Bruder, D.
10.1101/2021.02.19.431972 — Posted: 2021-02-19
Chyawanprash for the prevention of COVID-19 infection among healthcare workers: A Randomized Controlled Trial
Gupta, A., Madan, A., Yadav, B., Mundada, P. S., Singhal, R., Pandey, Y. K., Agarwal, R., Tripathi, A., Sharma, B. S., Rao, B., Gupta, B., Srikanth, N., Dhiman, K. S.
10.1101/2021.02.17.21251899 — Posted: 2021-02-19
Predicting the zoonotic capacity of mammal species for SARS-CoV-2
Fischhoff, I. R., Castellanos, A. A., Rodrigues, J. P. G. L. M., Varsani, A., Han, B. A.
10.1101/2021.02.18.431844 — Posted: 2021-02-19
Decreased neutralization of SARS-CoV-2 global variants by therapeutic anti-spike protein monoclonal antibodies
Tada, T., Dcosta, B. M., Zhou, H., Vaill, A., Kazmierski, W., Landau, N. R.
10.1101/2021.02.18.431897 — Posted: 2021-02-19

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).